Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Nanobiotix ( (NBTX) ) has shared an announcement.
On January 29, 2025, Nanobiotix announced its participation in several investor conferences scheduled for February and March 2025. These events, including the Guggenheim SMID Cap Biotech Conference and Leerink Global Healthcare Conference, will feature presentations by key company executives and are aimed at enhancing investor engagement and showcasing the company’s innovative approaches and progress in the biotechnology sector.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, with a focus on pioneering nanoparticle-based therapeutic approaches. The company, listed on Euronext Paris and Nasdaq, is dedicated to expanding treatment possibilities for cancer and other major diseases, owning more than 25 patent families related to oncology, bioavailability, biodistribution, and central nervous system disorders.
YTD Price Performance: 16.21%
Average Trading Volume: 33,945
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $163.3M
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.
